Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published April 16, 2020 | Published + Supplemental Material
Journal Article Open

A Guide to Targeting the Endocannabinoid System in Drug Design

Abstract

The endocannabinoid system (ECS) is one of the most crucial systems in the human organism, exhibiting multi-purpose regulatory character. It is engaged in a vast array of physiological processes, including nociception, mood regulation, cognitive functions, neurogenesis and neuroprotection, appetite, lipid metabolism, as well as cell growth and proliferation. Thus, ECS proteins, including cannabinoid receptors and their endogenous ligands' synthesizing and degrading enzymes, are promising therapeutic targets. Their modulation has been employed in or extensively studied as a treatment of multiple diseases. However, due to a complex nature of ECS and its crosstalk with other biological systems, the development of novel drugs turned out to be a challenging task. In this review, we summarize potential therapeutic applications for ECS-targeting drugs, especially focusing on promising synthetic compounds and preclinical studies. We put emphasis on modulation of specific proteins of ECS in different pathophysiological areas. In addition, we stress possible difficulties and risks and highlight proposed solutions. By presenting this review, we point out information pivotal in the spotlight of ECS-targeting drug design, as well as provide an overview of the current state of knowledge on ECS-related pharmacodynamics and show possible directions for needed research.

Additional Information

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Received: 16 March 2020; Accepted: 14 April 2020; Published: 16 April 2020. Author Contributions: Conceptualization, A.S. and J.I.S.; writing—original draft preparation, A.S. and K.Z.; writing—review and editing, M.G., T.P., and J.I.S.; funding acquisition, J.I.S. All authors have read and agreed to the published version of the manuscript. This research was funded by European Molecular Biology Organization installation Grant No. 2057 to J.I.S. and YIP EMBO to J.I.S.. The authors declare no conflict of interest.

Attached Files

Published - ijms-21-02778.pdf

Supplemental Material - ijms-21-02778-s001.pdf

Files

ijms-21-02778-s001.pdf
Files (2.7 MB)
Name Size Download all
md5:4266210dd515a7f627843f88fd24476a
153.6 kB Preview Download
md5:a00b8a5a52355e5e24be6b5381a4df13
2.6 MB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 20, 2023